Beyond PASI – Assessing the True Burden of Plaque Psoriasis in Clinical Practice
The Psoriasis Area and Severity Index (PASI) measures cutaneous disease severity and treatment response but does not directly…
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or…
ICOTYDE Approval Adds New Growth Angle To Johnson & Johnson Valuation Story
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…